High virological failure rate in HIV patients after switching to a regimen with two nucleoside reverse transcriptase inhibitors plus tenofovir

AIDS

Volumn 19, Issue 7, 2005, Pages 695-698

  Pérez Elías, Maria Jesús ^a   Moreno, Santiago ^a   Gutiérrez, Carolina ^a   López, Dolores ^a   Abraira, Victor ^a   Moreno, Ana ^a   Dronda, Fernando ^a   Casado, Jóse Luis ^a   Antela, Antonio ^a   Rodríguez, Miguel Angel ^a  

^a HOSPITAL RAMÓN Y CAJAL   (Spain)

Author keywords

K65R mutation; Nucleoside reverse transcriptase inhibitors; Tenofovir DF; Virological failure

Indexed keywords

ABACAVIR; DIDANOSINE; LAMIVUDINE; RIBAVIRIN; RNA DIRECTED DNA POLYMERASE; RNA DIRECTED DNA POLYMERASE INHIBITOR; STAVUDINE; TENOFOVIR; THYMIDINE DERIVATIVE; ZIDOVUDINE;

ADULT; FEMALE; GENE MUTATION; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; LACTIC ACIDOSIS; MAJOR CLINICAL STUDY; MALE; NONHUMAN; PRIORITY JOURNAL; REVIEW; SIDE EFFECT; TREATMENT FAILURE; TREATMENT OUTCOME; VIREMIA; VIROLOGY; VIRUS LOAD;

EID: 17844391588     PISSN: 02699370     EISSN: None     Source Type: Journal    
DOI: 10.1097/01.aids.0000166092.39317.42     Document Type: Review

References (14)

1. Louie M, Hogan C, Hurley A, Simon V, Chung C, Padte N, et al. Determining the antiviral activity of tenofovir disoproxil fumarate in treatment-naive chronically HIV-1-infected individuals. AIDS 2003; 17:1151-1156.
2. Farthing C, Khanlou H, Yeh V. Early virologic failure in a pilot study evaluating the efficacy of once daily abacavir (ABC), lamivudine (3TC) and tenofovir DF in treatment naive HIV-infected patients. In: Program and Abstracts of the 2nd International AIDS Society Conference on Pathogenesis and Treatment. Paris, France, 13-16 July 2003 [Abstract 43].
3. Gallant JE, Rodriguez AE, Weinberg W, Young B, Werger D, Lim ML, et al. Early non-response to tenofovir DF + abacavir (ABC) and lamivudine (3TC) in a randomized trial compared to efavirenz (EFV) + ABC and 3TC: ESS30009 unplanned interim analysis. In: Program and Abstracts of the 43rd Interscience Conference on Antimicrobial Agents and Chemotherapy. Chicago, IL, USA, 14-17 September 2003 [Abstract H-17223].
4. Landman R, Peytavin G, Descamps D, Brun Vezinet F, Benech H, Benalisherif A, et al. Low genetic barrier to resistance is a possible cause of early virologic failures in once-daily regimen of abacavir, lamivudine, and tenofovir: the Tonus study. In: Program and Abstracts of the 11th Conference on Retroviruses and Opportunistic Infections. San Francisco, CA, USA, 8-11 February 2004 [Abstract 52].
5. Jemsek J, Hutcherson J, Harper E. Poor virologic responses and early emergence of resistance in treatment naive, HIV-infected patients receiving a once daily triple nucleoside regimen of didanosine, lamivudine, and tenofovir DF. In: Program and Abstracts of the 11th Conference on Retroviruses and Opportunistic Infections. San Francisco, CA, USA, 8-11 February 2004 [Abstract 51].
6. Hoogewerf M, Regez RM, Schouten WE, Weigel HM, Frissen PH, Brinkman K, et al. Change to abacavir-lamivudine-tenofovir combination treatment in patients with HIV-1 who had complete virological suppression. Lancet 2003; 362:1979-1980.
7. Martinez E, Arnaiz JA, Podzamczer D, Dalmau D, Ribera E, Domingo P, et al. Substitution of nevirapine, efavirenz, or abacavir for protease inhibitors in patients with human immunodeficiency virus infection. N Engl J Med 2003; 349:1036-1046.
8. Staszewski S, Dauer B, Stürmer M, Haberl A, Müller A, Haberl A, et al. Predictors of loss of virologic response to tenofovir DF (TDF) therapy in HIV-1 patients. In: Program and Abstracts of the 2nd European HIV Drug Resistance Workshop. Rome, Italy, 11-13 March 2004 [Abstract 44].
9. Kearney PB, Isaacson E, Ebrahimi R, Zheng AK. The pharmacokinetics of abacavir, a purine nucleoside analog, are not affected by tenofovir DF. In: Program and Abstracts of the 43rd Interscience Conference on Antimicrobial Agents and Chemotherapy. Chicago, IL, USA, 14-17 September 2003 [Abstract A-1615].
10. Ray A, Vela J, Olson L, Eisenberg G, Fridland A. Lack of negative interaction between tenofovir and abacavir in human cells. In: Program and Abstracts of the 5th International Workshop on Clinical Pharmacology of HIV Therapy. Rome, Italy, 1-3 April 2004 [Abstract 2.3].
11. Gulick RM, Ribaudo HJ, Shikuma CM, Lustgarten S, Squires KE, Meyer WA III, et al. Triple-nucleoside regimens versus efavirenz-containing regimens for the initial treatment of HIV-1 infection. N Engl J Med 2004; 350:1850-1861.
12. Van Leeuwen R, Katlama C, Murphy RL, Squires K, Gatell J, Horban A, et al. A randomized trial to study first-line combination therapy with or without a protease inhibitor in HIV-1-infected patients. AIDS 2003; 17:987-999.
13. Parikh U, Koontz D, Sluis-Cremer N, Hammond J, Bacheler L, Schinazi R, et al. K65R: a multinucleoside resistance mutation of increasing prevalence exhibits bi-directional phenotypic antagonism with TAM. In: Program and Abstracts of the 11th Conference on Retroviruses and Opportunistic Infections. San Francisco, CA, USA, 8-11 February 2004 [Abstract 54].
14. Elion R, Cohen C, DeJesus E, Redfield R, Gathe J, Hsu R, et al. COL40263: Resistance and efficacy of once-daily trizivir and tenofovir DF in antiretroviral naive subjects. In: Program and Abstracts of the 11th Conference on Retroviruses and Opportunistic Infections. San Francisco, CA, USA, 8-11 February 2004 [Abstract 53].